Acasti Pharma's (TSXV:APO) Dr. Harlan Waksal Interviewed by Grant Howard of Howard Group - Video Hosted on www.InvestmentPitch.com
(Thomson Reuters ONE) -
Vancouver, British Columbia, March 2, 2012 - Grant Howard, President of Calgary,
Alberta based Howard Group, one of Canada's original full service Investor and
Financial Relations firms, recently interviewed Dr. Harlan Waksal.
In this, the third and final segment from Grant Howard's interview with Dr.
Harlan Waksal, he discusses his expectations for Acasti Pharma (TSXV:APO) once
it completes its Phase II study. He talks about Lovaza®'s and Amarin's billion
dollar valuations and Acasti's potential for a similar valuation.
Acasti Pharma is developing safe and effective pharmaceutical and medical
applications with an initial focus on cardiovascular disease by leveraging the
intellectual property, clinical data and know how developed by Neptune
Technologies and Bioressources Inc. (Nasdaq:NEPT) (TSX:NTB).
The Company is advancing a portfolio of bioactive ingredients of proprietary
novel omega-3 phospholipids through the pharmaceutical development pathway which
includes prescription medical foods (MF), over-the-counter products (OTC), and
prescription drugs (Rx). Phospholipids are the major component of cell membranes
and essential for all vital cell processes. They are one of the principle
constituents of High Density Lipoprotein (good cholesterol) and play, as such,
an important role in modulating cholesterol efflux.
Acasti Pharma's proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) stabilized by potent antioxidants. Evidence has
demonstrated the anti-inflammatory properties of EPA and DHA regulating
important biological functions including degenerative, arthritic, circulatory,
digestive, and brain diseases. Delivering omega-3s functionalized on
phospholipids helps optimize the omega-3 fatty acid therapeutic benefits. Potent
antioxidants contribute to proper physiological regulation preventing free
radical cellular damage, a common pathway for cardiovascular disease and
inflammation as well as neurodegenerative disease.
Neptune has carried out a number of clinical trials for various therapeutic
indications using Neptune Krill Oil (NKO®), a patented composition containing
the proprietary novel omega-3 phospholipids. A clinical multicenter, three-
month, prospective, randomized, double blind clinical study has been carried out
on 120 patients to assess the effectiveness in hyperlipidemia, a disease of
abnormal levels of LDL (bad cholesterol), HDL (good cholesterol) and
triglycerides. Hyperlipidemia promotes plaque formation and narrowing of the
arteries leading to heart attack, stroke and peripheral vascular and
neurodegenerative diseases.
InvestmentPitch.com in co-operation with the Howard Group, hosts a selection of
video presentations and interviews primarily from Howard Group's series of
Opportunity Knocks Investment Conferences. These conferences offer Howard
Group's clients an opportunity to showcase their companies to a select group of
investors.
This follow-up interview of Dr. Harlan Walsal is available for viewing on
InvestmentPitch.com. If this link is not enabled, please visit
www.investmentpitch.com and enter "Acasti" in the search box.
For more information about the company, please visit www.acastipharma.com, or
contact Dave Burwell of the Howard Group, at 403-221-0915 or email
dave(at)howardgroupinc.com.
InvestmentPitch.com is a multimedia company that provides a combined solution
for creating, hosting, and distributing financial video content across multiple
platforms to investors and financial professionals. InvestmentPitch.com
specializes in producing three minute videos based on news releases and research
reports.
CONTACT:
www.InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
BMorgan(at)InvestmentPitch.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: InvestmentPitch via Thomson Reuters ONE
[HUG#1591125]
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2012 - 20:23 Uhr
Sprache: Deutsch
News-ID 121291
Anzahl Zeichen: 4769
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 298 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Acasti Pharma's (TSXV:APO) Dr. Harlan Waksal Interviewed by Grant Howard of Howard Group - Video Hosted on www.InvestmentPitch.com"
steht unter der journalistisch-redaktionellen Verantwortung von
InvestmentPitch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
